Results from the PRIMA Trial: Comparison of the STHLM3 Test and Prostate-specific Antigen in General Practice for Detection of Prostate Cancer in a Biopsy-naïve Population

We compared STHLM3 and prostate-specific antigen in primary care as entry tests for magnetic resonance imaging (MRI) for suspicion of prostate cancer (PC). STHLM3 positivity (risk ≥11%) increased the diagnosis of clinically significant PC (grade group ≥2), but also increased diagnosis of grade group...

Ausführliche Beschreibung